BOSTON, March 25, 2019 /PRNewswire/ -- Bioelectronic medicine, referring to technologies that utilize electrical stimulation to treat conditions of the human body, has been in use for many decades for the treatment of cardiac conditions. As companies continue to develop and commercialize new technologies, we are expecting significant growth in the industry. In 2018, bioelectronic medicine was named by the World Economic Forum as one of the ten top technologies to change medical treatment. IDTechEx Research's market intelligence report Bioelectronic Medicine 2019 – 2029 forecasts the market to reach $60 billion by the year 2029.
To learn more about this exciting and disruptive technology, join the IDTechEx masterclass "Bioelectronic Medicine & Neuroprosthetics" on 12 April 2019 at the Estrel Convention Center in Berlin, Germany. For more information on the masterclass, please refer to https://www.idtechex.com/europe2019/show/en/masterclasses.
In this earnings season, we have already seen proof of significant growth in bioelectronic medicine. Double-digit growth has been reported in stimulators for the central nervous system (CNS), particularly, 2 spinal cord stimulators. The spinal cord stimulator is a device that is being used for the treatment of chronic pain. By disrupting the pain signaling pathways of the body with electrical stimulation, spinal cord stimulation is a drug-free solution that can address the ongoing opioid crisis. With increasing awareness of the value of bioelectronic medicine, more and more patients will be driven to bioelectronic therapies, rather than opioid painkillers.
In addition to the use of spinal cord stimulators to solve the opioid epidemic, there are countless other opportunities for market growth in bioelectronic medicine. LivaNova, a company that has developed a device for the treatment of epilepsy, reported 13 percent YoY growth in 2018. Axonics, a company that has recently commercialized a sacral nerve stimulator, brings much needed market disruption in an area dominated by medical device giant Medtronic. As market disruption in spinal cord stimulation has forced companies to innovate, patients suffering from overactive bladder and incontinence may look forward to new technologies to help manage their conditions.
To learn more about bioelectronic medicine, including technology and market trends, please refer to the IDTechEx report: Bioelectronic Medicine 2019 – 2029. Visit www.IDTechEx.com/bioelec or contact [email protected].
IDTechEx guides your strategic business decisions through its Research, Consultancy and Events services, helping you profit from emerging technologies. Find out more at www.IDTechEx.com.
Media Contact:Charlotte MartinMarketing & Research [email protected]+44(0)1223 812300
Related Links
Further IDTechEx Research
IDTechEx Show!
Advertisement
To learn more about this exciting and disruptive technology, join the IDTechEx masterclass "Bioelectronic Medicine & Neuroprosthetics" on 12 April 2019 at the Estrel Convention Center in Berlin, Germany. For more information on the masterclass, please refer to https://www.idtechex.com/europe2019/show/en/masterclasses.
Advertisement
In this earnings season, we have already seen proof of significant growth in bioelectronic medicine. Double-digit growth has been reported in stimulators for the central nervous system (CNS), particularly, 2 spinal cord stimulators. The spinal cord stimulator is a device that is being used for the treatment of chronic pain. By disrupting the pain signaling pathways of the body with electrical stimulation, spinal cord stimulation is a drug-free solution that can address the ongoing opioid crisis. With increasing awareness of the value of bioelectronic medicine, more and more patients will be driven to bioelectronic therapies, rather than opioid painkillers.
In addition to the use of spinal cord stimulators to solve the opioid epidemic, there are countless other opportunities for market growth in bioelectronic medicine. LivaNova, a company that has developed a device for the treatment of epilepsy, reported 13 percent YoY growth in 2018. Axonics, a company that has recently commercialized a sacral nerve stimulator, brings much needed market disruption in an area dominated by medical device giant Medtronic. As market disruption in spinal cord stimulation has forced companies to innovate, patients suffering from overactive bladder and incontinence may look forward to new technologies to help manage their conditions.
To learn more about bioelectronic medicine, including technology and market trends, please refer to the IDTechEx report: Bioelectronic Medicine 2019 – 2029. Visit www.IDTechEx.com/bioelec or contact [email protected].
IDTechEx guides your strategic business decisions through its Research, Consultancy and Events services, helping you profit from emerging technologies. Find out more at www.IDTechEx.com.
Media Contact:Charlotte MartinMarketing & Research [email protected]+44(0)1223 812300
Related Links
Further IDTechEx Research
IDTechEx Show!
View original content:http://www.prnewswire.com/news-releases/idtechex-research-bioelectronic-medicine---a-drug-free-solution-to-chronic-diseases-300817743.html
SOURCE IDTechEx
